Evaluation of cross‐neutralizing immunity following COVID‐19 primary series vaccination during the Omicron surge in Tanzania

• Published in: Journal of Medical Virology Vol. 96; no. 8; pp. e29822 - n/a
• Main Authors: Nkinda, Lilian, Barabona, Godfrey, Ngare, Isaac, Nkuwi, Emmanuel, Kamori, Doreen, Msafiri, Frank, Kunambi, Ponsian P., Osati, Elisha, Kidenya, Benson R., Chuwa, Harrison, Kinasa, Glory, Hassan, Frank E., Judicate, George P., Gasper, Joseph, Kisuse, Juma, Mfinanga, Sayoki, Senkoro, Mbazi, Ueno, Takamasa, Lyamuya, Eligius, Balandya, Emmanuel
• Format: Journal Article
• Language: English
• Published: United States Wiley 01.08.2024; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Africa; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; BQ.1.1; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Humans; Male; Middle Aged; Neutralization; Neutralization Tests; Neutralizing; neutralizing antibodies; SARS-CoV-2 - immunology; SARS‐CoV‐2; Serology; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Tanzania; Tanzania - epidemiology; Vaccination; Vaccines; Viral diseases; XBB.1.5; Young Adult; Tanzania; XBB.1.5; neutralizing antibodies; SARS‐CoV‐2; Africa; Tanzania; BQ.1.1

COVID‐19 vaccine became available in Tanzania during the first wave of the Omicron variant. During that time community seroprevalence of SARS‐CoV‐2 was already at 50%–80%. To date, it remains largely unknown whether ongoing vaccination with the primary series vaccines has any meaningful immune‐boost...